



Ventripoint
Diagnostics Ltd.

Putting the Heart into AI

Echocardiography with the Accuracy of cardiac MRI

December 2024

Forward Looking Statements

This presentation contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws, which is based upon Ventripoint Diagnostics Ltd.’s (“Ventripoint” or the “Company”) current internal expectations, estimates, projections, assumptions and beliefs. The forward-looking information and statements included in this presentation are made only as of the date of this presentation. Such forward-looking statements and forward-looking information include, but are not limited to, statements concerning future operations; the Company’s expectations with respect to the use of proceeds and the use of the available funds following completion of an offering of securities; the gross proceeds to be raised pursuant to such offering; and completion of an offering and the date thereof. Forward-looking statements or forward-looking information relate to future events and future performance and include statements regarding the expectations and beliefs of management based on information currently available to the Company. Such forward-looking statements and forward-looking information often, but not always, can be identified by the use of words such as “plans”, “expects”, “potential”, “is expected”, “anticipated”, “is targeted”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Forward-looking statements and forward-looking information are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements or forward-looking information, including, without limitation, risks and uncertainties relating to, among other things, general business and economic conditions; regulatory approval; completion of an offering; risks and uncertainties related to the ability to obtain or maintain necessary licenses, permits or intellectual property rights; the Company’s ability to raise sufficient financing on a timely basis, secure and restore relationships with its suppliers and development partners and retain qualified personnel; the Company’s expectation that it will undertake confirmatory trials with potential customers to support sales initiatives in new and existing markets; the Company’s intention to allocate a portion of its available capital towards its research efforts; the Company’s potential to have negative cash flow from operating activities and net losses in future periods as revenue from commercial activities continues to increase and that a portion of the proceeds from any offering will be used to fund negative cash flow from operating activities in future periods; the Company has a history of operating losses. It expects to incur net losses and may never achieve or maintain profitability; the Company may be unable to maintain or obtain partnerships for one or more of its product candidates, which could curtail future development and negatively affect its share price; the Company’s ability to meet the continued listing requirements of the TSXV; the availability of qualified employees and contractors; market competition; future results not being consistent with the Company’s expectations; termination of customer or distributor contracts; changes in regulation; and other risks of the industry in which the Company operates; the impact of COVID-19. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or forward-looking information.



About Ventripoint

Ventripoint provides rapid, affordable and accessible heart imaging through the application of Artificial Intelligence (AI) to cardiac ultrasound

- Publicly listed (TSXV: VPT OTCQB: VPTDF)
- Significant investment to date in developing and commercializing the VMS+ system - a proven ultrasound-based alternative to cardiac MRI (cMRI) that provides cardiologists greater confidence in the management of their patients
- Substantially de-risked: VMS+ is cleared for marketing and has been adopted by leading medical institutions in the United States, Europe, the UK and Canada
- We are raising growth capital to support market entry and launch of VMS+ V4.0



Current Situation

- ▶ Cardiac MRI (cMRI) is regarded as the gold standard for advanced or complex heart conditions, but is a complex and expensive modality and the relatively small installed base creates accessibility challenges
- ▶ cMRI not suitable for young patients and those with cardiac pacemakers
- ▶ Ultrasound is the world's fastest, safest and most affordable imaging modality
 - ▶ 2D cardiac ultrasound (echo) is widely used but dependent on operator ability and can generate inconsistent, unreliable measurements particularly for the right ventricle (RV)
 - ▶ Emerging technologies such as 3D Echo are limited by operator training and ability, and differences in patient anatomy and physiology



Ventripoint VMS+

- Built using a proprietary AI-based approach named Knowledge Based Reconstruction (KBR) that renders standard 2D echocardiograms into 3D volumetric images that provides cMRI-equivalent volumetric data to clinicians
- Faster, less expensive, more patient-friendly approach that can be used at the point-of-care and is less dependent on operator ability
- Enables more timely and responsive approach to managing cardiac health
- Product cleared for sales in the US, EU, UK, Canada, China and New Zealand




SickKids®




Knowledge Based Reconstruction

VMS+ built using AI and machine learning techniques


- ▶ Utilizing proprietary algorithms, we synthesized data from a proprietary cardiac MRI image catalogue to ensure cMRI levels of accuracy
- ▶ The KBR catalogue covers a wide array of clinical conditions and cardiac shapes
- ▶ VMS+ interfaces with all major brands of echocardiography systems




RV to PA
conduit/
Rastelli repair




Pulmonary
hypertension




Ebstein's
anomaly




RV to PA
conduit



Double Outlet
Right Ventricle



Tetralogy of
Fallot (TOF)



RV to PA
conduit



Our VMS+ Solutions

Ventripoint currently provides two products:

- ▶ VMS+ V3 connects to any 2D echo machine and generates 3D cardiac measurements with accuracy equivalent to cardiac MRI
- ▶ VMS+ Software for 3D Echo and MRI is a workstation solution that creates a 3D model of all 4 chambers of the heart from images generated by any commercially available 3D echo or MRI machine and generates reproducible and accurate volumetric measurements and ejection fractions



VMS+ Benefits

- ▶ Patient-friendly point-of-care modality
 - ▶ Can be performed at patient bedside (e.g ICU)
 - ▶ No pre-scan dietary restrictions or sedation required
 - ▶ Unlike cMRI patient is able to move during procedure
- ▶ Significantly faster and less expensive than cMRI
- ▶ Able to work with sparse data – generating results from echo studies that would otherwise need to be repeated
- ▶ Elimination of cMRI constraints for patients
- ▶ Children can be accompanied by a parent



\$2B Market Opportunity

- ♥ **Congenital Heart Defects**
 - Estimated 13.3 million patients worldwide
 - 1 million children + 1.4 million adults in the U.S.
 - Affects 1% of births in U.S. – 40,000 babies/year
- ♥ **Up to one-third of chemotherapy patients experience cardiotoxic effects**
 - VMS+ addresses current inability to accurately assess right ventricle ejection fractions using echo
 - 50 million patients per year worldwide
- ♥ **Pathologies related to the right ventricle such as Pulmonary Arterial Hypertension (PAH)**
 - 80 million patients worldwide



Market Situation

- ♥ VMS+ is the only echo solution able to accurately measure the volume and ejection fractions for all four chambers of the heart
- ♥ Echo machine manufacturers are acquiring AI ventures and integrating technology into their proprietary offerings to create differentiation and build competitive advantage.
- ♥ Valuations typically exceed USD\$100M
- ♥ Unique capabilities of VMS+, growing number of indications and adoption into clinical practice provide opportunity to create and monetize value



Growth Strategy

- ♥ Leverage validation of VMS+ evidenced by 60+ papers and references and product use within teaching centres
- ♥ Accelerate and scale adoption by driving awareness of benefits of adoption within routine clinical practice
- ♥ Direct development activities towards enhanced automation features and integration within clinical workflows
- ♥ Pursue B2B relationships with imaging, structural heart and therapeutic vendors
- ♥ Introduce subscription option to enable recurring revenue model



Management Team

Hugh MacNaught, President and CEO

Fortune 100 trained executive with thirty years experience in the innovation, development, financing, and commercialisation of medical and life science technologies. His familiarity with research translation and technology development within early stage companies includes several years as a venture capitalist and founding, leading and financing technology ventures.

Matt Dobson, BEng, MBA, Marketing Director

Track record of delivering successful products to market quickly and cost-effectively, using rapid and low-cost techniques to reduce risk and test assumptions. Matt is passionate about finding emerging market trends and creating insight-driven businesses that address unmet needs and solve real problems.

Scott Hammerling, Strategic Sales Leader

Experienced sales leader with a demonstrated history within the medical device industry. Experience includes ultrasound, radiology, software and capital equipment



Board of Directors

George Adams, Ph.D., ICD.D, Chairman

Dr. Adams is a serial entrepreneur and has held research and executive roles within Boston Scientific, Pfizer, and Corvita. He has raised more than \$100 million and achieved successful exits.

Hugh MacNaught, President & CEO, Director

Fiona Fitzgerald, Director

Ms. Fitzgerald is National Zone Leader for Cytiva Life Science, formerly part of GE. Ms. Fitzgerald chaired NSERC's CREATE program, and holds board memberships in CIMTEC, MDCC, and is on the Advisory Board for the Centre of Bioengineering and Biotechnology in Waterloo University.

Randy Aucoin, Director

Mr. AuCoin is President and CEO of Exact Imaging, the world leader in high-frequency ultrasound for early detection of prostate cancer. He has raised over \$60 million of venture capital and has extensive experience in finance, sales and marketing, and operations.



Use of Proceeds

- ▶ Market entry and product launch for VMS+ V4
- ▶ Expansion of commercial team
- ▶ Expanding marketing outreach, sales and customer support to sustain and grow market share in NA, Europe and the U.K.
- ▶ Double installed base in 2025
- ▶ Engage reimbursement consultancy in US
- ▶ Establish commercial relationships in Asia and MENA regions: distribution, JVs and manufacturing



Capitalization

| | | |
|------------------------|---------------|--|
| Shares Outstanding | 161.4M | No anti-dilution protection |
| Options @\$0.25 | 9.7M | Employees, directors and contractors. Various expiry dates. |
| Warrants @\$0.68 | 15.6M | Expire 27 September 2026 |
| Fully Diluted | 186.7M | |
| Recent Share Price | CDN\$.10 | |
| 52-Week Range | CDN\$.10 -.36 | |
| Market Cap | CDN\$16M | |
| TSXV: VPT OTCQB: VPTDF | | |





Ventripoint
Diagnostics Ltd.

Putting the Heart into AI

For more information please contact:

Hugh MacNaught

President and CEO

Tel: +1 604 671 4201

E-mail : hmacnaught@ventripoint.com